A randomized clinical trial evaluating Hydralazine’s efficacy in early-stage Alzheimer’s disease: The EHSAN Study

A randomized clinical trial evaluating Hydralazine’s efficacy in early-stage Alzheimer’s disease: The EHSAN Study

Abstract Alzheimer’s Disease (AD), a neurodegenerative disorder escalating worldwide, remains incurable with existing interventions merely mitigating symptoms. Hydralazine, an antihypertensive agent, has displayed neuroprotective potential in AD animal models via amplification of mitochondrial funct...

Full description

Saved in:
Bibliographic Details
Main Authors: Masoud Mirzaei, Nastaran Ahmadi, Behnam Bagheri Fahraji, Ali Mellat Ardekani, Abolghasem Rahimdel, Mohammad Hossein Soltani, Seyed Mojtaba Yassini Ardekani, Reza Bidaki, Fatemeh Hosseini Kasnavie, Ghasem Dastjerdi, Marzieh Aboutorabi, Hamid Mirzaei
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Alzheimer’s disease
Clinical trial
Hydralazine
ADAS-cog
Peanut butter test
SIRT1/SIRT5
Online Access:https://doi.org/10.1038/s41598-024-79616-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-79616-4

Similar Items